PMID- 30779662
OWN - NLM
STAT- In-Data-Review
LR  - 20190322
IS  - 1546-3141 (Electronic)
IS  - 0361-803X (Linking)
VI  - 212
IP  - 4
DP  - 2019 Apr
TI  - Prebiopsy Biparametric MRI for Clinically Significant Prostate Cancer Detection
      With PI-RADS Version 2: A Multicenter Study.
PG  - 839-846
LID - 10.2214/AJR.18.20498 [doi]
AB  - OBJECTIVE: The purpose of this study was to evaluate the diagnostic performance
      of the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) with
      respect to prebiopsy MRI with and without dynamic contrast enhancement in the
      detection of clinically significant cancer (CSC). MATERIALS AND METHODS: A total 
      of 113 patients with prostate cancer who underwent radical prostatectomy and
      prebiopsy multiparametric 3-T MRI (mpMRI) that included T2-weighted imaging, DWI,
      and dynamic contrast-enhanced MRI (DCE-MRI) were enrolled in a retrospective
      study conducted at two institutions. For detecting CSC at prebiopsy mpMRI with
      DCE-MRI and biparametric MRI (bpMRI) without DCE-MRI, two independent
      radiologists using PI-RADSv2 scored suspicious lesions in all patients. RESULTS: 
      CSC was identified in 74.3% (84/113) of patients. For CSC detection rate, no
      statistical differences between bpMRI and mpMRI were found for any PI-RADS score 
      (p > 0.05). For cancer in the peripheral zone, reader 1 upgraded 22 lesions and
      reader 2 upgraded 13 lesions from PI-RADS score 3 at bpMRI to PI-RADS 4 (3 + 1)
      at mpMRI. The CSC detection rate of PI-RADS 3 + 1 lesions at mpMRI (reader 1,
      63.6%; reader 2, 69.2%) was slightly greater than that of PI-RADS 3 lesions at
      bpMRI (reader 1, 53.8%; reader 2, 60.0%), which was not statistically different
      (p > 0.05). Interreader agreement on PI-RADS scoring was moderate for both bpMRI 
      (kappa = 0.540) and mpMRI (kappa = 0.478). CONCLUSION: For detecting CSC, the
      diagnostic performance of prebiopsy bpMRI without DCE-MRI is similar to that of
      mpMRI with DCE-MRI.
FAU - Choi, Moon Hyung
AU  - Choi MH
AD  - 1 Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The
      Catholic University of Korea, Seoul, Republic of Korea.
AD  - 2 Cancer Research Institute, Seoul St. Mary's Hospital, College of Medicine, The 
      Catholic University of Korea, Seoul, Republic of Korea.
FAU - Kim, Chan Kyo
AU  - Kim CK
AD  - 3 Department of Radiology, Samsung Medical Center, Sungkyunkwan University School
      of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, Republic of Korea.
AD  - 4 Department of Medical Device Management and Research, Samsung Advanced
      Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul,
      Republic of Korea.
FAU - Lee, Young Joon
AU  - Lee YJ
AD  - 1 Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The
      Catholic University of Korea, Seoul, Republic of Korea.
FAU - Jung, Seung Eun
AU  - Jung SE
AD  - 1 Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The
      Catholic University of Korea, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20190219
PL  - United States
TA  - AJR Am J Roentgenol
JT  - AJR. American journal of roentgenology
JID - 7708173
OTO - NOTNLM
OT  - MRI
OT  - PI-RADS
OT  - diagnosis
OT  - multicenter study
OT  - prostate cancer
EDAT- 2019/02/20 06:00
MHDA- 2019/02/20 06:00
CRDT- 2019/02/20 06:00
PHST- 2019/02/20 06:00 [pubmed]
PHST- 2019/02/20 06:00 [medline]
PHST- 2019/02/20 06:00 [entrez]
AID - 10.2214/AJR.18.20498 [doi]
PST - ppublish
SO  - AJR Am J Roentgenol. 2019 Apr;212(4):839-846. doi: 10.2214/AJR.18.20498. Epub
      2019 Feb 19.